ApicHope Pharmaceutical Group Co., Ltd. CLass A

ApicHope Pharmaceutical Group Co., Ltd. CLass A

SSZSE:300723
26.16
CNY
-0.49
(-1.84%)
0.39EPS
82.52P/E
15.08BMarket Cap
Apr 23Next Earn

Total Valuation

CNY

As of September 30, 2026, ApicHope Pharmaceutical Group Co., Ltd. CLass A carries a market capitalization of 15.08B, placing it among publicly traded companies globally. Its enterprise value stands at 15.98B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap15.08B
Enterprise Value15.98B

Important Dates

ApicHope Pharmaceutical Group Co., Ltd. CLass A's next confirmed earnings release is scheduled for April 23, 2027.

Earnings Date4/23/2027

Share Statistics

As of September 30, 2026, ApicHope Pharmaceutical Group Co., Ltd. CLass A has 453.18M shares outstanding.

Shares Outstanding453.18M

Valuation Ratios

As of September 30, 2026, ApicHope Pharmaceutical Group Co., Ltd. CLass A trades at a trailing price-to-earnings ratio of 82.52. The price-to-sales ratio is 20.32, and the price-to-book ratio stands at 8.52.

PE Ratio82.52
PS Ratio20.32
PB Ratio8.52
P/TBV Ratio11.20

Enterprise Valuation

As of September 30, 2026, ApicHope Pharmaceutical Group Co., Ltd. CLass A trades at an EV/EBITDA multiple of 78.87 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 21.74 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 78.87 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 15.98B versus a market cap of 15.08B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales21.74
EV / EBITDA78.87
EV / EBIT78.87

Financial Position

As of September 30, 2026, ApicHope Pharmaceutical Group Co., Ltd. CLass A maintains a current ratio of 1.44, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 111.96, indicating elevated leverage, while an interest coverage ratio of 3.90 demonstrates adequate ability to service its debt obligations.

Current Ratio1.44
Quick Ratio0.97
Debt / Equity111.96
Debt / EBITDA9.96
Interest Coverage3.90

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, ApicHope Pharmaceutical Group Co., Ltd. CLass A posted a return on equity (ROE) of 10.10, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 3.89, measuring how efficiently the asset base is converted into earnings. The company generates approximately 567,850.80 in revenue per employee across its workforce of 1,294.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.53 indicates how many times ApicHope Pharmaceutical Group Co., Ltd. CLass A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)10.10
Return on Assets (ROA)3.89
Revenue Per Employee567,850.80
Employee Count1,294.00
Inventory Turnover1.53

Taxes

CNY

Over the twelve months ended September 30, 2026, ApicHope Pharmaceutical Group Co., Ltd. CLass A recorded an income tax benefit of -39.09M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 136.31M, leaving 180.94M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax-39.09M

Stock Price Statistics

CNY

As of the close on November 17, 2026, ApicHope Pharmaceutical Group Co., Ltd. CLass A's stock has declined approximately 47.69% over the past 52 weeks. The 50-day moving average sits at 31.76, while the 200-day moving average is 35.09.

52-Week Price Change-47.69%
50-Day Moving Average31.76
200-Day Moving Average35.09

Income Statement

CNY

Over the twelve months ended September 30, 2026, ApicHope Pharmaceutical Group Co., Ltd. CLass A generated 734.80M in revenue and converted that into 180.94M in net income, yielding earnings per share of 0.39. EBITDA reached 202.56M, while operating income came in at -263.04M.

Revenue734.80M
Gross Profit358.52M
Operating Income-263.04M
Pretax Income136.31M
Net Income180.94M
EBITDA202.56M
EBIT202.56M
Earnings Per Share (EPS)0.39

Balance Sheet

CNY

As of September 30, 2026, ApicHope Pharmaceutical Group Co., Ltd. CLass A holds 1.15B in cash and equivalents against 2.02B in total debt, resulting in a net debt position of 856.50M. Total book value stands at 1.77B, with working capital of 531.08M providing operational flexibility.

Cash & Cash Equivalents1.15B
Total Debt2.02B
Net Debt856.50M
Equity (Book Value)1.77B
Book Value Per Share3.90
Working Capital531.08M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-94.68M

Margins

Over the twelve months ended September 30, 2026, ApicHope Pharmaceutical Group Co., Ltd. CLass A posted a gross margin of 48.79, reflecting its pricing power and cost economics. The operating margin of -35.80 and net profit margin of 24.62 provide insight into operational efficiency.

Gross Margin48.79
Operating Margin-35.80
Pretax Margin18.55
Profit Margin24.62
EBITDA Margin27.57

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, ApicHope Pharmaceutical Group Co., Ltd. CLass A paid dividends of 0.11 per share. The dividend payout ratio of 27.98 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 5.39, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to ApicHope Pharmaceutical Group Co., Ltd. CLass A shareholders.

Dividend Per Share0.11
Payout Ratio27.98
Shareholder Yield5.39

Stock Splits

ApicHope Pharmaceutical Group Co., Ltd. CLass A's most recent stock split took place on May 24, 2023 with a 2:3 split ratio.

Last Split Date5/24/2023
Split Ratio2:3

Scores

As of September 30, 2026, ApicHope Pharmaceutical Group Co., Ltd. CLass A has an Altman Z-Score of 4.01, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.01